Table 1.

Patient Characteristics Including Plasma and CSF Darunavir Concentrations for Each Subject^a

									Drv concentrations (ng/ml)
Patient number	Visit number	Sex	Age	CD4 cell count(×106/liter)	Plasma VL (log10 copies/ml)	CSF VL (log10 copies/ml)	Antiretroviral treatment in addition to drv/r	Time on ART(weeks)	Plasma	CSF
1	1	m	57	320	2.51	<1.30	zdv + 3TC + abc + T20 + ral	13.0	2680	34.9
	2	m	57	110	<1.30	<1.30	zdv + 3TC + abc + ral	43.5	8550	96.5
2	1	m	46	160	<1.30	<1.30	zdv + 3TC + abc + ral	16.0	3870	25.6
	2	m	46	190	<1.30	<1.30	zdv + 3TC + abc + ral	66.0	1800	19.6
3	1	m	61	430	3.73	<1.30	zdv + 3TC + abc + T20	12.0	3210	33.5
	2	m	61	370	1.82	<1.30	zdv + 3TC + abc + T20	50.0	6740	53.8
4	1	m	43	80	<1.30	<1.30	zdv + 3TC + abc + ral	20.5	4060	35.5
	2	m	43	140	<1.30	<1.30	zdv + 3TC + abc + ral	56.0	3990	23.5
5	1	f	22	0	5.20	5.66	zdv + 3TC + abc + ral	0.5	12900	212.0
6	1	m	49	38	4.05	<1.30	zdv + 3TC + tdf + ral	0.9	9120b	43.9b
	2	m	49	92	2.66	<1.30	zdv + 3TC + tdf + ral	4.0	3770	28.7
7	1	m	50	133	4.10	4.00	tdf + ftc + ral	1.0	4590	15.9
	2	m	50	140	2.35	1.32	tdf + ftc + ral	4.9	2820	20.1
8	1	m	54	168	2.38	<1.30	zdv + 3TC + abc	2.5	3550	64.8

^aVL, viral load; ART, antiretroviral treatment; m, male; f, female; zdv, zidovudine; 3TC, lamivudine; abc, abacavir; drv/r, darunavir/ritonavir; T20, enfuvirtide; ral, raltegravir; tdf; tenofovir; ftc, emtricitabine.

^bSampling time unknown.